Related Experiment Videos
[Intravenous verapamil in hypertrophic myocardiopathy. A study using Doppler ultrasound]
G de la Morena Valenzuela1, J A Ruipérez Abizanda, F Picó Aracil
1Unidad de Cardiología-Hemodinámica, Hospital Virgen de la Arrixaca, Murcia.
Insights
Intravenous verapamil improved left ventricular diastolic function in hypertrophic cardiomyopathy patients. This study confirms verapamil
Area of Science:
- Cardiology
- Pharmacology
- Medical Imaging
Context:
- Hypertrophic cardiomyopathy (HCM) is a complex cardiac condition.
- Left ventricular diastolic dysfunction is a key feature of HCM.
- Doppler-echocardiography is a vital tool for assessing cardiac function.
Purpose:
- To evaluate the effects of intravenous verapamil on diastolic and systolic function in HCM patients.
- To assess changes in specific echocardiographic parameters after verapamil administration.
Summary:
- Intravenous verapamil administration in 31 HCM patients led to significant improvements in diastolic function, including decreased 'a' wave velocity and shortened isovolumic relaxation period.
- Verapamil also reduced peak ejection flow velocity, indicating a beneficial effect on systolic function.
- No correlation was found between patient demographics or disease characteristics and the observed functional improvements.
Impact:
- This research validates the beneficial role of intravenous verapamil in managing HCM.
- Findings suggest verapamil not only reduces the ventricular gradient but also enhances diastolic function.
- The study underscores the utility of Doppler-echocardiography in demonstrating therapeutic effects in HCM.
Abstract:
The effect of one intravenous dose of verapamil on left ventricular diastolic and systolic flow was studied by Doppler-echocardiography in 31 patients with hypertrophic cardiomyopathy. On diastolic flow, verapamil induced a decrease in "a" wave velocity (1.02 + 0.37 vs 0.91 + 0.29 m/seg, p less than 0.01), and in its relation with maximal protodiastolic velocity (1.08 + 0.56 vs 0.89 + 0.37, p less than 0.01), and a shortening in the isovolumic relaxation period (0.076 + 0.031 vs 0.068 + 0.02, p less than 0.05). On the ejection flow, verapamil decreased the peak velocity (2.82 + 1.28 vs 2.42 + 1.18 m/seg, p less than 0.001). Nor age, sex, ventricular mass, gradient, neither hypertrophic cardiomyopathy's classification relates with changes after intravenous verapamil. There were no adverse effects. This study by Doppler-echocardiography confirms the beneficial ++ effect of intravenous verapamil in patients with hypertrophic cardiomyopathy not only on gradient reduction but also in the improvement on left ventricular diastolic function.